DBV Technologies | DBVT - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
DBV Technologies USD 58.02M 8.54M 2025-12
Esperion Therapeutics USD 300.36M 451K 2026-03
Galectin Therapeutics USD 14.62M 1.98M 2024-06
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Incyte USD 1.49B 25.52M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03